Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 12 Carcinoma, Non-Small-Cell Lung 6 Breast Neoplasms 5 Triple Negative Breast Neoplasms 4 Stomach Neoplasms 4 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Fallopian Tube Neoplasms 3 Advanced Pancreatic Cancer 3 Esophageal Neoplasms 2 Biliary Tract Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Staging IV NSCLC 1 Squamous Cell Carcinoma of Lung 1 Solid Tumor 1 Sertoli-Leydig Cell Tumor 1 Recurrence 1 Peritoneal Neoplasms 1 Pancreatic Cancer Non-resectable 1 Pancreatic Adenocarcinoma 1 Ovarian gynandroblastoma 1 Obesity 1 Neurotoxicity Syndromes 1 Neoplasms 1 Nasopharyngeal Neoplasms 1 Nasopharyngeal Carcinoma 1 Liver Neoplasms 1 HER2-negative Breast Cancer 1 HER2+ Breast Cancer 1

Interventions

dehydroftorafur 1 Taxes 1 Radiotherapy, Intensity-Modulated 1 Radiation 1 Platinum 1 Paclitaxel 1 Immune Checkpoint Inhibitors 1 Fluorouracil 1 Cisplatin 1 Chemoradiotherapy 1 Carboplatin 1 Capecitabine 1 1,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Anal Canal Carcinoma × Taxes × Clear all

NCT02560298 2023-06-22

InterAACT

Eastern Cooperative Oncology Group

Phase 2 Unknown

Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡